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Abstract
Objectives: To investigate the relation between primary chronic insomnia and insulin sensitivity, visceral adiposity, non
alcoholic fatty liver disease and neuroendocrine hormones.
Materials and Methods: In a case-controlled, prospective clinical trial 13 women with primary chronic insomnia according
to DSM-IV criteria were compared to 12 healthy controls matched for age, sex, BMI, body composition and menopausal
status. All participants had a sleep assessment including polysomnographic studies and neuropsychiatric evaluation. Insulin
sensitivity was evaluated using the euglycaemic hyperinsulinemic clamp. Hepatic fat content, visceral adipose tissue and
intramyocellular lipid accumulation were assessed using magnetic resonance imaging and spectroscopy. The hormonal
stress axis was evaluated by measurements of midnight and early morning salivary cortisol, urinary catecholamines and
plasma metanephrines. Body composition was determined using body impedance analysis and indirect calorimetry.
Results: Although the diagnosis of primary chronic insomnia was made by established clinical criteria, standard
polysomongraphic studies failed to identify altered sleep continuity and architecture when compared to matched controls.
However, women with primary chronic insomnia showed significantly higher midnight salivary cortisol concentrations (1.46
vs. 0.76 nmol/l, p= 0.02), indicating dysregulation of the hypothalamo-pituitary-adrenal (HPA) axis. Plasma glucose and lipid
concentrations, insulin sensitivity, hepatic and intramyocellular fat content, visceral adipose tissue mass and body
composition did not differ between the two groups.
Conclusion: Healthy women with clinically diagnosed primary chronic insomnia demonstrate a dysregulation of circadian
cortisol secretion despite normal sleep continuity and architecture. Increased midnight cortisol levels, however, were not
associated with impaired metabolism of glucose and lipids.
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Introduction
Diabetes mellitus type 2 has an increasing prevalence in our
society [1,2]. Changes in dietary habits and diminished physical
activity are important contributors to this development. Another
behavioral change that has occurred during the same time period
is the increased prevalence of sleep curtailment [3]. Both animal
and clinical studies have established the importance of an intact
circadian rhythm for the regulation of metabolic processes and
sleep deprivation has been linked to impaired glucose and lipid
metabolism [3,4,5,6,7,8]. The identification of so-called clock
genes has further highlighted the importance of circadian rhythms
for the regulation of metabolic processes. These genes promote the
production of downstream transcription factors, which in turn
regulate genes involved in metabolic pathways [4]. Interestingly,
mice homozygous for a loss of function mutation in the clock genes
develop features of the metabolic syndrome [5]. Several clinical
studies in humans also suggested a relation between sleep
deprivation and insulin resistance. Spiegel et al., for example,
showed that short time sleep restriction promoted an impairment
of glucose tolerance in healthy young men [6]. Sleep apnea has
been identified as a common trait of the metabolic syndrome and
its treatment led to improved insulin sensitivity in obese patients
[7,9]. Moreover, a recently published meta-analysis suggested that
quantity and quality of sleep predicts the risk of developing
diabetes [8]. The impact of acute sleep loss on metabolism has
been thoroughly investigated, but the relation between chronic
sleep loss and metabolism still needs further analysis [10].
PLOS ONE | www.plosone.org 1 April 2013 | Volume 8 | Issue 4 | e61780
The aim of the present investigation was therefore to assess
whether (i) patients diagnosed with primary chronic insomnia
show alterations of glucose and lipid metabolism when compared
to age, sex and body mass index (BMI)-matched healthy controls,
(ii) the potential metabolic alterations could promote the
development of features of type 2 diabetes and its associated
metabolic disorders, such as dyslipidaemia, visceral adiposity and
non-alcoholic fatty liver disease. Moreover, we were interested to
see (iii) whether the-pituitary-adrenal axis and the sympathoadre-
nal system, which play a role in the regulation of glucose
metabolism, may be dysregulated in patients with primary
insomnia. To this purpose we defined the metabolic alterations
in patients with primary insomnia and compared them to age,
BMI and menopausal status-matched healthy controls in a case-
controlled, prospective trial.
Materials and Methods
The protocol was approved by the Human Ethics Committee of
Basel. All participants gave written informed consent prior to the
study (Clinical Trial Registration Number: NCT00442624).
Patients with primary chronic insomnia were recruited from the
Depression and Sleep Research Unit, Psychiatric University
Clinics, Basel, and by advertisements in local newspapers.
Participants responding to advertisements were screened by a
structured telephone interview. Those deemed eligible were
invited to join a screening visit in the outpatient department of
the Division of Endocrinology, University Hospital Basel (see
Fig 1). Written informed consent was obtained from all
participants.
Age and BMI- matched healthy controls were recruited by
internet advertisements from the local population and underwent
the same screening procedures as patients. The inclusion criterion
for insomniacs was diagnosis of primary chronic insomnia based
on clinical history. Exclusion criteria for insomniacs were any
other known sleeping disorders but primary chronic insomnia.
Exclusion criteria for healthy controls were any kind of sleeping
disorders. Importantly, controls and insomniacs with diabetes
mellitus, dyslipidaemia (LDL cholesterol .4.9 mmol/l and/or
increased fasting triglycerides .1.7 mmol/l), those taking medi-
cation interfering with glucose or lipid metabolism, or presenting
with any other significant comorbidity and pregnant and breast
feeding women were not eligible to participate.
The diagnosis of ‘‘primary chronic insomnia’’ was made using
the Diagnostic and Statistic manual of Mental Disorders IV
(DSM-IV) criteria [11]. This means the predominant complaint
was difficulty initiating or maintaining sleep, or non-restorative
sleep, for at least one month. Further on the sleep disturbance had
to cause clinically significant distress. It did not occur exclusively
during the course of narcolepsy, breathing-related sleep disorder,
circadian rhythm sleep disorder, parasomnia or a mental disorder.
Additionally the disturbance was not due to the direct physiolog-
ical effects of a substance or a general medical condition.
To exclude any organic cause for the sleeping disorder or a
metabolic disease, a thorough clinical investigation was performed,
and screening blood samples were drawn.
To exclude a psychiatric cause for the sleep disorder the Mini-
international Neuropsychiatric Interview (M.I.N.I.) [12] and the
Beck Depression Inventory (BDI) [13] were performed.
The M.I.N.I. is a short structured diagnostic interview designed
to assess psychiatric diagnoses for clinical trials [12].
The BDI is a 21-question multiple choice self-report inventory
for measuring the severity of depression [13]. On a global
depression score with a possible range of 0-63, a score of .15
indicates the existence of depression.
Patients and controls eligible to participate in the study protocol
based on the results of the screening visit were to undergo a
polysomnographic study (PSG) with a portable monitoring system
(Siesta H, Compumedics, Abbotsford, Australia) in order to
analyze sleep continuity and architecture.
Participants were monitored for two non-consecutive nights in
the course of one week. Electrodes for the electroencephalogram
were placed according to the international 10/20-system using
C3/ C4 positions occipital and A1/ A2 positions postauricular.
The polysomnographic study further included a submental
electromyogram for muscle tone, an electrooculogram for eye
movement and an electrocardiogram for heart rate. Respiration
was monitored using two elastic bands placed around abdomen
and thorax registering respiratory excursion. Finger oxymetry
provided information about blood oxygenation. Limb movements
were measured with two electrodes applied to the Musculi tibialis
anteriores.
After the PSG installation patients and controls were discharged
to spend the night in their usual environment at home. The next
morning patients and controls returned and the polysomnograph
was removed.
After the first night all participants were manually scored for
restless legs syndrome and sleep apnea using the ProFusion PSG
software (CompumedicsH, Abbotsford, Australia) according to
standardized criteria [14].
Participants having a periodic limb movement index (PLM-
index) exceeding 15 and those having a PLM-index with arousal
exceeding 5 were excluded from our study, assuming the presence
of a restless legs syndrome. Participants having a respiratory
deficiency index (RDI) exceeding 5 were also excluded from our
study since it indicates sleep apnea.
The second night of the patients was manually analysed
regarding quality of sleep using the Profusion PSG software
(CompumedicsH, Abbotsford, Australia). The following items were
evaluated: time of sleep, sleep efficiency ([sleep time ? 100/ bed
time]), number of arousals, wake up time after initiation of sleep,
latency of REM-sleep (time between initiation of sleep and first
REM epoch), percentage of the various sleep stages, PLM-index,
PLM-index with arousal and RDI.
On the evening before the metabolic studies patients were
admitted to the Clinical Research Center (CRC) of the University
Hospital Basel. A standard dinner was served containing 30 g
protein, 90 g carbohydrate and 30 g fat. Participants were asked
to remain fasting until the end of the study. After receiving
instructions for 12 h urine collection for catecholamine measure-
ments and salivary samples for cortisol measurements at 11.30
p.m. and 06.00 a.m., patients were discharged.
All participants were readmitted to the outpatient department
the next morning. Cortisol levels were determined employing a
competitive solid phase time-resolved fluorescence immunoassay
with fluorometric end point detection (DELFIA; Wallac, Turku,
Finnland). Adrenaline and noradrenaline were measured in 12 h
urine using high performance liquid chromatography (CoulArray
HPLC system, ESA Biosiences, MA, USA).
Plasma metanephrine concentrations were measured in fasting
blood samples using high performance liquid chromatography
(CoulArray HPLC system, ESA Biosiences, MA, USA).
Magnetic resonance imaging (MRI) and proton magnetic
resonance spectroscopy (1H MRS) were performed to gain
information about liver fat content, the quantity of adipose tissue
and intracellular triglyceride concentrations [15,16,17].
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For measurements of hepatic lipid accumulation and visceral
adipose tissue MRI data were acquired on a 1.5 Tesla whole body
system. (Magnetom Avanto, Siemens Healthcare, Erlangen,
Germany). A 6 element array coil placed over the right lateral
abdomen of the patients and appropriate channels of an 8 element
spine coil were used for signal reception.
Anatomical MRI was performed in order to position the
2?2?2 cm3 voxel used in the localized spectroscopy experiment.
Spectroscopic data were acquired using a double spin echo PRESS
sequence without water suppression. RF-pulses with optimised
excitation profiles were used in order to achieve good voxel
localization and to avoid signal contamination from subcutaneous
fat. Four signal averages were collected during one breath hold.
Spectroscopic data was analysed using the software package
NUTS (Acorn NMR Inc., Livermore, USA). The acquisition of six
data sets with spin echo times of 30 ms, 40 ms, 50 ms, 60 ms,
70 ms and 80 ms allowed estimation of fat and water contribu-
tions and therefore excluded relaxation phenomena. The lipid
signal results from chemically shifted proton resonances corre-
sponding to methyl and methylene groups occupying different
positions on lipid molecules with frequencies found in the range
2140 Hz to 2245 Hz with a major peak at about 2220 Hz,
corresponding to methylene groups in (CH2)n acyl chains. The
MRI liver fat percentage was then reported as the spin density of
the aliphatic 1H signal divided by the sum of the spin densities of
aliphatic and water 1H signals. To exclude outliers, the
spectroscopic experiment described above was performed for
two different voxels in each subject.
The amount of visceral adipose tissue was obtained from
multislice T1-weighted MR imaging. Fatty tissue appears bright in
T1-weighted MR images and can be easily segmented by
thresholding. Subcutaneous fat was separated manually from
visceral fat. Visceral and subcutaneous fat volumes were calculated
by multiplying the number of voxels containing visceral and
subcutaneous fat, respectively by the voxel volume.
To assess intramyocellular lipids (IMCL), spectroscopic MRI
data were acquired on a 3.0 Tesla scanner (Magnetom Allegra,
Siemens, Erlangen, Germany). Participants were placed in supine
position; their right leg was positioned in the center of the
radiofrequency headcoil. Anatomical T1-weighted MR imaging
was performed in order to define the region of interest. Localized
proton spectra were collected using a PRESS sequence. A voxel
(10610612 mm3) was placed in the Musculus tibialis anterior
trying to avoid macroscopic visible fat accumulations as well as
vessel structures. To optimize the homogeneity of the magnetic
field volume selective shimming was accomplished [18]. IMCL
concentration was calculated as the ratio between the area under
the IMCL peak and the area under the water line.
To assess body composition, body impedance analysis (Body-
impedance Analyzer Model BIA 101, Akern Srl Florence Italy)
was performed. Body composition was calculated using the
Bodygram software (Akern Srl Florence Italy).
Figure 1. Recruitment of participants.
doi:10.1371/journal.pone.0061780.g001
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Indirect calorimetry (Deltatrac II, Datex) was used to examine
rates of energy production and substrate oxidation. To assess
oxygen consumption, carbon dioxide production and the respira-
tory quotient (RQ) indirect calorimetry (Deltatrac II, Datex) was
performed.
An euglycaemic hyperinsulinemic clamp was performed to
assess insulin sensitivity of glucose turnover [19].
An indwelling teflon catheter was placed into an antecubital
vein for infusions and a retrograde cannula in a hand vein for
blood collection. A 3 hour insulin-glucose clamp began with a
primed/continuous insulin infusion (20 mU/m2/min) and a
variable infusion of 20% dextrose to maintain plasma glucose
levels at 5.560.5 mmol/l. Arterialized blood was collected during
the clamp every 5 min for immediate determination of plasma
glucose levels using an automated glucose analyzer (2300 STAT
Plus, YSI Bioanalytical Products). The portion of metabolized
glucose (M) was calculated as follows: M=GINF – s.
GINF was the glucose concentration in the infusate [mg/
(kg6min)] and s the space correction factor. Total M ( mmol/ kg/
min) was calculated from the means of the four 10 min periods
from 150 to 180 min of the euglycaemic hyperinsulinaemic clamp.
The space correction factor (s) was calculated as follows:
s = 3.7956(SA/BW)6(G1–G2) SA was the body surface area (m2),
and BW the body weight (kg), G1 the initial plasma gucose
concentration (mmol/l) and G2 the final plasma glucose concen-
tration (mmol/l).
Plasma insulin levels were measured to ascertain a steady state
during the euglycaemic hyperinsulinaemic clamp. Plasma C-
peptide concentrations were measured to evaluate if the insulin
concentration in the infusate was sufficient to suppress endogenous
insulin production.
Insulin and C-peptide levels were determined employing solid-
phase, two-site chemiluminescent immunometric assays (IMMU-
LITE 2000 Insulin or C-peptide, respecitvely, from Siemens, UK).
Mann Whitney U tests and correlation analyses were performed
using statistical software (JMP Statistical Software, SAS Institute
Inc); p,0.05 was defined significant. Initially demographic
variables were compared between patients with insomnia and
healthy controls. In addition, sleep variables were compared to
know if patients and healthy controls differed with respect to sleep.
All data are expressed as means6SD.
Results
Baseline characteristics (Table 1)
Age, BMI, waist circumference, blood pressure, serum choles-
terol, HDL-cholesterol, triglycerides, ASAT (aspartate transami-
nase), ALAT (alanine transaminase), GGT (Gamma-glutamyl
transferase) and CRP (C-reactive protein) did not differ signifi-
cantly between 13 women with chronic insomnia and 12 matched
healthy control women. Thus, patients and healthy controls were
well matched for demographic, anthropometric and biochemical
characteristics.
The Mini- International Neuropsychiatric Interview showed
throughout negative answers to all questions in all patients and
controls enrolled in the study. Thus, a psychiatric disease was
excluded in all participants of the study.
The BDI showed no statistically significant difference regarding
depressive symptoms.
Sleep assessment
All patients suffered from primary chronic insomnia according
to DSM IV criteria while controls had a normal sleep-wake-cycle.
In the PSG study the wake time after sleep onset (Table 2) was
longer in insomniacs than in controls (p = 0.05) whereas no
statistically significant differences were found between patients and
controls with regard to dimensions of both the remaining sleep
continuity and sleep architecture (Table 2).
Table 1. Baseline characteristics.
Insomniacs Controls p-Value
N 13 12
Age (years) 51.768.0 52.869.9 0.36
BMI (kg/m2) 22.762.6 22.461.5 0.68
Waist circumference (cm) 78.3610.2 77.767.1 0.81
Systolic blood pressure
(mmHg)
125.0618.0 116.668.5 0.43
Diastolic blood pressure
(mmHg)
76.166.3 81.6612.0 0.15
Cholesterol (mmol/l) 5.461.0 5.561.1 0.82
HDL (mmol/) 2.060.4 2.160.4 0.56
Triglyceride (mmol/l) 0.960.3 0.860.2 0.58
ASAT (U/l) 25.266.3 24.764.9 0.97
ALAT (U/l) 26.9614.6 1867.3 0.07
cGT (U/l) 25.0620.7 16.865.9 0.23
CRP (mg/l) 3.060.7 2.361.1 0.15
Beck Depression Inventory
(BDI)
3.162.3 2.162.1 0.31
Mann Whitney U tests were performed; all data are expressed as means6SD.
doi:10.1371/journal.pone.0061780.t001
Table 2. Parameters of sleep continuity and sleep
architecture (polysomnographic study).
Insominacs Controls p-Value
Number of awakenings 12.364.7 11.6 64.2 0.97
Wake time after sleep onset
(min) *
78.0657.6 45.9 641.2 0.05
Sleep onset latency (min) 17.2621.0 18.0 618.3 0.74
Total sleep time (min) 342.1684.2 328.6 694.5 0.80
Sleep efficiency (%) 76.5617.6 82.2 615.9 0.19
Stage REM latency (min) 101.0 664.1 93.9 659.9 0.45
Wake time (min) 66.2 648.7 44.3 641.1 0.16
Stage REM (min) 71.5 627.3 56.9 631.8 0.30
Stage 1 sleep (min) 19.2 610.0 13.9 68.9 0.13
Stage 2 sleep (min) 202.5656.3 222.9694.8 0.58
Stage 3 sleep (min) 25.4 613.4 28.8 614.5 0.64
Stage 4 sleep (min) 21.3 622.7 11.2 616.8 0.12
Stage REM (% sleep time) 5.7 62.4 5.2 65.5 0.10
Stage 1 (% sleep time) 20.7 64.4 17.2 67.8 0.35
Stage 2 (% sleep time) 60.2 66.7 66.0 613.0 0.09
Stage 3 (% sleep time) 7.2 62.9 8.1 66.8 0.93
Stage 4 (% sleep time) 6.0 66.1 3.2 64.4 0.11
Mann Whitney U tests were performed; all data are expressed as means6SD;
*indicates statistical significance.
doi:10.1371/journal.pone.0061780.t002
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Salivary cortisol, urinary catecholamines, plasma
metanephrines
Midnight salivary cortisol concentrations were higher in
insomniacs compared to healthy controls (p = 0.02). No significant
differences were observed for morning salivary cortisol concen-
trations. Urinary 12 h excretion rates of noradrenaline were
significantly higher in controls compared to insomniacs (p = 0.02),
whereas no significant difference was found in urinary excretion
rates of adrenalin and dopamine, nor plasma concentrations of
metanephrines (Table 3, Fig. 2). No significant correlations
Figure 2. Midnight and morning salivary cortisol concentrations in insomniacs and controls. Midnight values were significantly higher in
insomniacs than in controls (p = 0.02), whereas morning values did not differ significantly (p = 0.18).
doi:10.1371/journal.pone.0061780.g002
Figure 3. Correlation of salivary cortisol, baseline characteristics, glucose and lipid metabolism as well as catecholamines; filled
circles represent controls, filled triangles represent insomniacs; p values including all participants are presented.
doi:10.1371/journal.pone.0061780.g003
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between cortisol levels and baseline characteristics, parameters of
sleep assessed by PSG, urinary catecholamines, visceral and
subcutaneous adipose tissue volume, liver fat content, intramyo-
cellular lipid content and insulin sensitivity in insomniacs alone
and in all participants together were identified (Fig. 3).
MR spectroscopy of liver and muscle
No statistically significant differences of liver fat content, visceral
and subcutaneous adipose tissue volume and intramyocellular
lipids were found between insomniacs and controls (Table 4).
Euglycaemic hyperinsulinaemic clamp technique
No statistically significant difference of insulin-induced glucose
uptake, i.e. no difference of insulin sensitivity between patients and
controls was found (Table 4).
Body impedance analysis (BIA) and resting energy
expenditure
Healthy controls had a significantly higher amount of total body
water when compared to patients (p = 0.04). No significant
differences in cell mass, weight of fat and non-fat tissue, as well
as muscle mass were detected. Respiratory quotients and resting
energy expenditure were comparable between patients and
controls (Table 5).
Discussion
The present study investigated whether primary chronic
insomnia in otherwise healthy, normal weight women is associated
with metabolic and neuroendocrine changes that promote the
onset of diabetes. To this aim extensive metabolic phenotyping
and sleep studies were performed in 13 women diagnosed with
primary chronic insomnia and 12 healthy controls matched for
gender, age, BMI, body composition and menopausal status.
Regarding features of the sleep disturbance, it was unexpected
to observe that all patients with primary chronic insomnia
according to DSM IV criteria showed no major differences in
polysomnographic data compared to controls. We only found a
significantly higher amount of wake time after sleep onset in
patients. There was no significant group difference concerning the
various sleep stages. Similar results were found in other studies
where only 50–60% of individuals with established diagnostic
criteria for insomnia actually showed differences in the poly-
somnographic studies compared to normal sleepers [20].
A possible explanation for this discrepancy could be the fact that
for the traditional PSG scoring a vast amount of data collected
during one PSG study is drastically reduced and artificially
segmented during analysis. Therefore, the limited representation
of sleep monitored by traditional PSG may not fully represent the
quality of sleep [20].
Midnight salivary cortisol concentrations were significantly
increased in patients with primary chronic insomnia when
compared to controls, indicating dysregulation of the hypotha-
lamo-pituitary-adrenal (HPA) axis. Midnight as well as morning
salivary cortisol levels were not associated with baseline charac-
teristics, metabolism of glucose and lipids and catecholamines.
Similar alterations in evening cortisol levels were observed
previously in a study with 11 healthy young men after one night
Table 3. Salivary cortisol, urinary catecholamines and dopamine, and plasma metanephrines and 12-hour excretion rates of
urinary metanephrines.
Insomniacs Controls p-Value
Salivary cortisol 11:30 p.m. (nmol/l)* 1.4 61.4 0.7 60.4 0.02
Salivary cortisol 6:00 a.m. (nmol/l) 10.3 66.3 7.3 63.5 0.18
Urinary adrenaline excretion rate (nmol/12 h) 9.9611.1 15.5 618.1 0.06
Urinary noradrenaline excretion rate (nmol/12 h)* 9.5623.8 16.0 643.4 0.02
Urinary dopamine 12 h excretion rate (nmol/12 h) 13.66215.2 12.26294.8 0.64
Plasma normetanephrine (nmol/l) 0.2 60.0 0.3 60.0 0.15
Plasma metanephrine (nmol/l) 0.1 60.0 0.1 60.0 0.91
Mann Whitney U tests were performed; all data are expressed as means6SD; *indicates statistical significance.
doi:10.1371/journal.pone.0061780.t003
Table 4. Visceral and subcutaneous adipose tissue volume, liver fat content, intramyocellular lipid content (MR spectroscopy) and
insulin sensitivity (euglycaemic hyperinsulinaemic clamp).
Insomniacs Controls p-Value
Visceral fat volume (cm3) 1140 6913 7936582 0.47
Subcutaneous fat volume (cm3) 4410 62558 3476 62268 0.32
Hepatic lipid content (fat signal/water signal in%) 1.8 62.6 1.0 60.5 0.74
Intramyocellular lipid content (IMCL signal/water
reference61000)
4.5 62.1 3.9 61.51 0.66
M value 4.961.1 5.4 61.4 0.54
GINF (glucose infusion rate) (mg/kg6min) 5.0 61.1 5.5 61.4 0.44
Mann Whitney U tests were performed; all data are expressed as means6SD.
doi:10.1371/journal.pone.0061780.t004
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of sleep deprivation [21]. A correlation between elevated evening
plasma cortisol levels and sleep deprivation has also been
demonstrated in the Whitehall II study, where a cohort of nearly
7000 subjects recruited from the general population was investi-
gated [22]. Further on in infants suffering from infantile colic,
fragmented sleep patterns and increased saliva cortisol levels were
related [23]. The results of these and our own studies suggest that
dysregulation of HPA is a common feature of both acute and
chronic sleep curtailment. However, the mechanisms involved are
unclear. It is well known that corticotropin-releasing hormone and
cortisol have adverse effects on sleep quality [24,25]. Noteworthy,
insomnia can also provoke a stress reaction, including the
activation of the HPA-axis [26]. Therefore, it remains unknown
whether sleep deprivation leads to increased cortisol levels or if the
dysregulation of the HPA-axis causes primary chronic insomnia.
Abnormal cortisol levels may precipitate more severe stages of
insomnia. However, to proof this hypothesis, longitudinal studies
are required.
Interestingly, we found a slightly increased urinary noradren-
aline excretion in controls as compared to insomniacs while
excretion rates of adrenaline and dopamine and plasma concen-
trations of metanephrines were not significantly different. These
results suggest that the sympatho-adrenal system did not play a
pathogenic role in the development of primary chronic insomnia
in our patients. Despite extensive investigations employing glucose
clamp and in vivo MRI techniques no metabolic features
indicating increased diabetes risk or incipient diabetes, such as
peripheral insulin resistance or increased intramyocellular or
hepatic lipids could be detected in our study population. At a first
glance this seems unexpected since several authors reported
disturbed glucose metabolism or incident diabetes in patients with
short sleep duration [27,28], sleep disorders such as obstructive
sleep apnea [29] and healthy subjects subjected to sleep
deprivation [6,10,30]. In our study, healthy physically active
women with primary chronic insomnia, i.e. subjects reporting
difficulty initiating or maintaining sleep, or non-restorative sleep
leading to subjective distress and increased wake time after sleep
but normal sleep architecture were investigated. The presence of a
relatively mild sleep disorder in otherwise healthy women may
explain the absence of metabolic disturbances and agrees with the
results of Keckeis et al. who could not find impaired glucose
tolerance in patients with chronic primary insomnia [31].
Nevertheless, sleep curtailment in subjects having adopted to an
unhealthy lifestyle with physical inactivity and ad libitum food
intake resulting in weight gain may precipitate impaired glucose
metabolism [32].
A limitation of our study may be the relatively small number of
participants. However, the variances of the parameters measured
were similar to previous studies, and according to our sample size
calculation the chance for a statistical error type II was small.
In summary, we found that chronic primary insomnia is
associated with dysregulation of the HPA-axis, as indicated by
increased midnight salivary cortisol concentrations. Although
elevated night time cortisol levels have been demonstrated to
more profoundly impact glucose metabolism when compared to
increased morning cortisol levels [33], we could not demonstrate
any changes in glucose and lipid metabolism that may precede the
onset of diabetes. Nevertheless, due to the well described
detrimental metabolic effects of cortisol oversecretion, the increase
in nocturnal cortisol levels may convey an increased risk to develop
diabetes and dyslipidema.
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